1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TAKE Solutions Limited

TAKE Solutions Limited

TAKE.BO
TAKE Solutions LimitedIN flagBombay Stock Exchange
23.64
INR
-0.59
- -
3.47BMarket Cap
TAKE Solutions Limited
TAKE.BO
(Bombay Stock Exchange)

Recent

price

23.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
41.69
58.64
69.33
67.96
60.87
85.81
105.46
120.62
139.53
151.34
52.93
44.63
12.93
0.25
- -
3.7
- -
Revenue per Share
6.13
7.13
6.62
4.83
5.82
9.97
11.22
12.19
12.13
-0.85
-30.91
-53.5
-6.86
-8.18
2.53
0.74
2.73
Basic EPS, GAAP
-12.25
6.12
3.63
2.18
3.81
-0.26
-7.2
-1.91
2.71
1.96
9.03
6.09
-0.85
0.1
-1.11
-0.28
- -
Free Cash Flow per Basic Share
0.21
1.13
1.86
1
1
1.23
1.03
1
1.94
0.49
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.58
10.22
15.32
16.98
20.62
28.44
36.85
47.04
52.88
51.57
20.33
-33.07
-38.68
-46.87
-44.08
1.01
- -
Book Value per Share
2.68
6.55
14.09
17.69
24.38
21.14
42.89
69.84
45.16
47.19
28.57
8.5
3.71
-0.73
1.39
2.11
- -
Tangible Book Value per Share
120
120
120
120
120
120
127
132
146
146
146
146
146
146
148
147
147
Basic Weighted Avg Shares
5,003
7,037
8,320
8,155
7,304
10,301
13,446
15,872
20,390
22,129
7,740
6,526
1,891
36
- -
542
- -
Sales/Revenue/Turnover
16.92
16.83
13.83
8.63
12.35
13.54
13.17
12.81
11.35
0.8
-19.37
-9.21
3.08
-181.04
- -
-3.55
- -
Operating Margin (%)
48
79
223
373
203
248
874
1,041
1,535
1,669
1,154
959
168
79
- -
- -
- -
Depreciation Expense
736
856
795
580
699
1,197
1,431
1,605
1,773
-124
-4,520
-7,823
-1,003
-1,196
375
108
403
Net Income, GAAP
8.12
18.33
16.95
1.59
6.37
13.86
11.44
14.96
17.29
- -
- -
- -
- -
- -
- -
3.62
- -
Effective Tax Rate (%)
14.7
12.16
9.55
7.11
9.57
11.62
10.64
10.11
8.7
-0.56
-58.4
-119.86
-53.03
-3,320.93
- -
20.02
- -
Profit Margin (%)
1,478
1,766
2,023
1,993
2,091
1,895
4,435
7,630
4,482
5,391
3,366
796
-107
-539
76
185
- -
Working Capital
1,313
1,235
830
576
8
676
488
545
389
2,127
1,613
278
139
66
- -
- -
- -
LT Debt
2,818
3,796
4,661
5,183
5,805
6,792
9,532
13,367
15,274
15,854
11,243
1,806
1,086
-89
205
310
- -
Total Equity
17.79
19.4
15.86
10.25
11.82
13.73
14.24
12.06
10.32
- -
- -
- -
- -
- -
-31.04
-7.19
- -
Return on Invested Capital (%)
34.81
31.82
21.85
14.55
14.88
20.25
20.59
20.24
17.28
- -
- -
- -
- -
- -
-6.06
-3.51
-5.87
Return on Capital (%)
64.02
96.34
51.85
29.93
30.98
40.64
35.27
29.47
25.48
-1.62
-85.98
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
146
- -
Market Capitalization
2,338
982
1,322

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
236
- -
Cash, Cash Equivalents & STI
- -
34
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
160
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-44.27%
-102.46%
51.03%
Free Cash Flow
121.77%
-320.31%
-74.79%
Net Income, GAAP
329.52%
-39.44%
-71.04%
Sales/Revenue/Turnover
- -
- -
1,404.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36
1
- -
132
36
2025
- -
- -
- -
- -
- -
2026
- -
- -
542
- -
542

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.36
-0.11
-0.15
- -
-8.18
2025
-0.26
-0.11
3.26
-0.33
2.53
2026
-0.06
0.07
0.29
- -
0.74

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BeiGene, Ltd. (BGNE)
Pharmosa Biopharm Inc. (6875.TWO)
Innovation1 Biotech Inc. (IVBT)
ACADIA Pharmaceuticals Inc. (ACAD)
Elevation Oncology, Inc. (ELEV)
Rallybio Corporation (RLYB)
Business
TAKE Solutions Limited, along with its associated entities, delivers specialized services within the expansive life sciences and intricate supply chain management sectors globally. Operating prominently as Navitas Life Sciences, the company provides comprehensive support for clinical research, the development of generic drugs, advanced data science applications, regulatory compliance, and pharmacovigilance and safety monitoring, all powered by technological prowess. Furthermore, it integrates digital and mobile platforms to foster patient-centric insights in the life sciences domain, alongside offering payer solutions that facilitate access to billing information via cloud technology. The organization also presents digital solutions for payers and providers, incorporating personalized medicine, wellness programs, and patient engagement strategies. Additionally, it offers medical device solutions, encompassing technological advancements like chip-level programming, integration with wearables, DICOM devices, patient-reported outcome measures (PROM), nano devices, and various sensor technologies. This enterprise was established in 2000 and maintains its principal offices in Chennai, India.